Bio-Techne Corporation

Equities

TECH

US09073M1045

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-11 EDT			5-day change	1st Jan Change
54.14 ^USD	-0.50%		+1.88%	-24.84%

07-09	TD Cowen Initiates Bio-Techne at Buy With $65 Price Target	MT
06-25	Bio-Techne Corporation, Q3 2025 Earnings Call, May 07, 2025

Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10:40 AM

Published on 2025-06-10 at 12:05, updated on 2025-06-10 at 20:05

Presenter Speech
Matthew Sykes (Analysts)

Good morning, everyone. My name is Matt Sykes, the life science tools and diagnostics analyst at Goldman Sachs. And today, I have the pleasure of welcoming Jim

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Bio-Techne Corporation

TD Cowen Initiates Bio-Techne at Buy With $65 Price Target	07-09	MT
Bio-Techne Corporation, Q3 2025 Earnings Call, May 07, 2025	06-25
Bio-Techne Corporation and U.S. Pharmacopeia Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development	06-24	CI
Bio-Techne, US Pharmacopeia Partner to Distribute Reference Standards	06-24	MT
Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10:40 AM	06-10
Bio-Techne Corporation Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03:45 PM	06-05
Deutsche Bank Adjusts Bio-Techne Price Target to $66 From $70	06-05	MT
Bio-Techne Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02:40 PM	06-03
Argus Adjusts Price Target on Bio-Techne to $65 From $90	05-30	MT
Wells Fargo Initiates Bio-Techne at Overweight With $59 Price Target	05-30	MT
Bio-Techne Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10:40 AM	05-13
Bio-Techne Corporation to Showcase Next-Generation Solutions for Gene and Cell Therapy At American Society of Gene & Cell Therapy 2025	05-12	CI
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating	05-09	MT
Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on February 1, 2022.	05-08	CI
Benchmark Adjusts Bio-Techne Price Target to $75 From $95	05-08	MT
Stifel Nicolaus Adjusts Bio-Techne Price Target to $60 From $75, Maintains Hold Rating	05-08	MT
Bio-Techne Collaborates With Genome Engineering Firm Kytopen	05-08	MT
Kytopen Corp. and Bio-Techne Corporation Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing	05-08	CI
Citigroup Adjusts Bio-Techne Price Target to $55 From $70, Maintains Neutral Rating	05-08	MT
Deutsche Bank Adjusts Bio-Techne Price Target to $70 From $84, Maintains Buy Rating	05-08	MT
RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating	05-08	MT
Evercore ISI Cuts Price Target on Bio-Techne to $60 From $70	05-07	MT
Bio-Techne exceeds profit expectations, announces new share buyback plan	05-07	RE
Bio-Techne Fiscal Q3 Non-GAAP Earnings, Sales Increase	05-07	MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q3 Revenue $316.2M, vs. FactSet Est of $317.2M	05-07	MT